O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET)-Reference-Cited by-同舟云学术

O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET)

Published:2019-04 Issue:4 Volume:51 Page:595-599
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Lemelin Annie,Barritault Marc,Hervieu Valérie,Payen Léa,Péron Julien,Couvelard Anne,Cros Jérome,Scoazec Jean-Yves,Bin Sylvie,Villeneuve Laurent^ORCID,Lombard-Bohas Catherine,Walter Thomas^ORCID

Funder

French National Cancer Institute

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference39 articles.

1. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States;Yao;J Clin Oncol,2008

2. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option?;Delaunoit;Eur J Cancer,2004

3. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas;Strosberg;Cancer,2011

4. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors;Walter;Clin Colorectal Cancer,2010

5. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin;Auernhammer;Gut,2011

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of O(6)-methylguanine-DNA methyltransferase in cancer therapy: insights into alkylators, pharmacogenomics, and others;Frontiers in Oncology;2024-07-11

2. Treatment, Prognostic Markers, and Survival in Thymic Neuroendocrine Tumors, with Special Reference to Temozolomide-Based Chemotherapy;Cancers;2024-07-10

3. Predictive Factors of Response to Streptozotocin in Neuroendocrine Pancreatic Neoplasms;Journal of Clinical Medicine;2023-12-07

4. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?;Best Practice & Research Clinical Endocrinology & Metabolism;2023-09

5. Neuroendocrine Tumors: Genomics and Molecular Biomarkers with a Focus on Metastatic Disease;Cancers;2023-04-12